# Transplantation Using Hepatitis C Positive Donors, A Safety Trial

> **NCT04017338** · PHASE3 · UNKNOWN · sponsor: **Jordan Feld** · enrollment: 40 (estimated)

## Conditions studied

- Lung Transplant Infection
- Heart Transplant Infection
- Kidney Transplant Infection
- Kidney Pancreas Infection
- Hepatitis C

## Interventions

- **DRUG:** Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet
- **DRUG:** Ezetimibe 10Mg Oral Tablet
- **DEVICE:** Ex Vivo Lung Perfusion

## Key facts

- **NCT ID:** NCT04017338
- **Lead sponsor:** Jordan Feld
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-06
- **Primary completion:** 2020-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04017338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04017338, "Transplantation Using Hepatitis C Positive Donors, A Safety Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04017338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*